Cognition Therapeutics (CGTX) Profit After Tax (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Profit After Tax of -$4.6 million for Q1 2026, up 46.11% year-over-year from -$3.1 million in Q1 2025, and down 36.7% quarter-over-quarter from -$3.3 million in Q4 2025.
Cognition Therapeutics (CGTX) Profit After Tax (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Profit After Tax for 7 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 46.11% year-over-year to -$4.6 million; the TTM figure through Mar 2026 stood at -$19.6 million (up 41.55% YoY), while the FY2025 annual figure was -$23.5 million, up 30.86% from the prior year.
- Profit After Tax declined to -$4.6 million in Q1 2026 per CGTX's latest filing, from -$3.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$3.3 million in Q4 2025 and bottomed at -$9.9 million in Q3 2024.
- Historically, Profit After Tax has averaged -$6.4 million across 5 years, with a median of -$6.6 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 1821.08% — and 2025, when it soared 58.4%.
- Cognition Therapeutics' Profit After Tax stood at -$5.2 million in 2022, then sank by 57.1% to -$8.1 million in 2023, then increased by 1.28% to -$8.0 million in 2024, then jumped by 58.4% to -$3.3 million in 2025, then plunged by 36.7% to -$4.6 million in 2026.
- Business Quant data shows CGTX's Profit After Tax at -$4.6 million in Q1 2026, -$3.3 million in Q4 2025, and -$4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | -3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.93 Mn |
| Mar 31, 2026 | -4.57 Mn |
| Dec 31, 2025 | -3.34 Mn |
| Sep 30, 2025 | -4.93 Mn |
| Jun 30, 2025 | -6.73 Mn |
| Mar 31, 2025 | -8.48 Mn |
| Dec 31, 2024 | -8.04 Mn |
| Sep 30, 2024 | -9.94 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Mar 31, 2024 | -9.15 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -6.75 Mn |
| Jun 30, 2023 | -4.73 Mn |
| Mar 31, 2023 | -6.17 Mn |
| Dec 31, 2022 | -5.18 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -5.75 Mn |
| Mar 31, 2022 | -3.84 Mn |
| Dec 31, 2021 | -7.33 Mn |
| Sep 30, 2021 | -3.11 Mn |